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Background: The benefit of Ginkgo biloba for the treatment of dementia remains controversial. The aim of this
study was to evaluate the efficacy and safety of Ginkgo biloba in patients with dementia in whom administration
effects were reported using meta-analysis.
Methods: We searched MEDLINE, Embase, the Cochrane databases, and Ichushi for controlled trials of Ginkgo biloba
for the treatment dementia. Clinical characteristics and outcomes were extracted. Meta-analysis results were expressed
as standard mean differences (SMDs) in scores of the Syndrome Kurztest (SKT), Alzheimer’s Disease Assessment Scale
Cognitive Subscale (ADAS-Cog) for cognition efficacy, or odds ratios (ORs) for dropouts and adverse drug reactions.
Results: Thirteen studies using the extract EGb761 met our inclusion criteria, which were duration of 12 to 52 weeks
and daily dose of more than 120 mg, and included a total of 2381 patients. Meta-analysis was performed by using 9 of
13 studies, 7 of which used the SKT and 2 ADAS-Cog (dose 120 mg, 26 weeks) scores as efficacy parameters. In
meta-analysis of all patients, SMDs (95% confidence interval [CI]) in the change in SKT scores (7 studies) were in favor of
Ginkgo biloba over placebo (SMD = –0.90 [–1.46, –0.34]), but 2 studies that used ADAS-Cog did not show a statistically
significant difference from placebo for ADAS-Cog (–0.06 [–0.41, 0.30]). For Alzheimer’s disease (AD) and vascular
dementia (VaD) subgroups, SMDs [95% CI] in SKT in the combined AD and VaD subgroup (–1.07 [–1.66, –0.47]) and AD
subgroup (–1.36 [–2.27, –0.46]) were in favor of Ginkgo biloba over placebo. In terms of daily dose of Ginkgo biloba in
the combined AD and VaD subgroup, SMD in SKT score in 240-mg daily dose groups was significantly greater than with
placebo (–0.71 [–1.28, –0.14]). Dropout rates for any reason did not differ between two groups, but dropout rates due to
side effects were significantly lower in Ginkgo biloba groups compared with placebo groups (OR = 1.72 [1.06, 2.80]).
Conclusions: Taking a 240-mg daily dose of Ginkgo biloba extract is effective and safe in the treatment of dementia.
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The standardized Ginkgo biloba extract EGb761 (Anatom-
ical Therapeutic Chemical [ATC] code N06DX02) is clas-
sified as a therapeutic agent for dementia along with
cholinesterase inhibitors and memantine in the ATC clas-
sification. Commission E of Germany [1], a committee
that evaluates the efficacy and safety of herbal prepara-
tions, recognizes EGb761 as a medicine. The criteria for
recognition as a medicine are improvement of symptoms,
such as disturbance of memory, lack of concentration, de-
pression, dizziness, tinnitus, etc., due to degenerative* Correspondence: mochizuki-my@pha.keio.ac.jp
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unless otherwise stated.dementia, vascular dementia, or menopausal disorders.
The standard composition of EGb761 preparations is
22.0% to 27.0% flavonoids and 5.0% to 7.0% terpenoids
(ginkolides A, B, C; bilobalide; etc.) as active ingredients,
and less than 5 ppm of ginkgolic acid, which is an allergen.
Flavonoids inactivate deleterious toxic active oxygen, and
terpenoids act as antagonists of platelet activating factor
and exert neuroprotection in the brain [1,2]. By combining
these pharmacological activities, Ginkgo biloba is thought
to improve memory and learning ability, blood flow in the
microcirculation, hypoxia tolerance in brain cells, and
blood viscosity due to its antioxidant, antiinflammatory,
and other activities.
Although Ginkgo biloba extract has been reported to
be effective in the treatment of vertigo [3], tinnitus [4],tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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consistent, conclusive results were not reported because
of small sample sizes in many. Although there are a few
meta-analyses [7-10] and a Cochran review [11] in the lit-
erature, they mainly focused on the efficacy of Ginkgo
biloba rather than safety, except for the reviews by Jiang
et al. [10] and Birks and Evans [11]. They evaluated mul-
tiple measures of cognitive outcome by extracting the re-
sults of the ADAS-Cog, SKT, etc. to determine efficacy.
Ginkgo biloba extract is sold as a health food product
in Japan and as an over-the-counter (OTC) preparation
in Germany. It would be safer if it were also sold as an
OTC preparation under the management of healthcare
professionals such as pharmacists in Japan. For the safe
use of Ginkgo biloba extract products from the view-
point of both patients and healthcare professionals, the
risk-and-benefit balance is important. The aim of this
study was therefore to evaluate both the efficacy based
on a single measure of cognitive outcome and safety
based on various outcomes of Ginkgo biloba in the treat-
ment of dementia using the meta-analysis approach.
Methods
Data sources
To identify relevant clinical studies, an electronic search
was conducted using MEDLINE (1966–January 2014),
Embase (1974–January 2014), the Cochrane Library
(Issue 1 of 12, January 2014), and Japana Centra Revuo
Medicina (Ichushi) (1981–September 2014). The terms
and study design used in the searches were “Ginkgo,” or
“icho” (in Japanese), “Alzheimer disease,” “cognitive de-
fect,” “dementia,” and “multiinfarct dementia,” limited to
“randomized controlled trial.” In Ichushi, original articles
and randomized controlled trials were searched under
the type of article and study design. We imposed no lan-
guage limitation in the searches. Additionally, a manual
search of reference listings from all of the articles re-
trieved from the electronic databases was performed.
Inclusion criteria
The inclusion criteria of articles were that the studies: 1)
were designed as double-blind, randomized, placebo-
controlled trials; 2) had similar patients, study endpoints,
dosage and administration, route of administration, dur-
ation of administration, etc.; 3) included patients with
Alzheimer’s disease (AD), vascular dementia (VaD),
mixed dementia with AD and VaD, and mild dementia.
The standard mean difference (SMD) in the average
value of the Syndrome Kurztest (SKT) [12] and Alzhei-
mer’s Disease Assessment Scale cognitive subscale
(ADAS-Cog) [13] scores was used as the efficacy end-
point. The dropout rate and incidence of adverse events
were used as safety endpoints. The primary outcome
was the SMD of the average value of cognitive measuresconsisting of the SKT and ADAS-Cog, and dropout rate
due to adverse events, respectively. Secondary outcomes
included subanalysis of disease classification, dose, and
administration duration for efficacy endpoints and drop-
out rate by reason and dose and incidence of adverse
events for safety endpoints.
Three investigators (MH, YO, MS) applied the inclu-
sion criteria independently to the articles retrieved.
When disagreements occurred, all three conferred to ar-
rive at a consensus. The quality of the studies retrieved
was assessed using the Jadad score [14]. Only studies
that received a score of 3 points or more were included
in the meta-analysis. The three investigators scored the
studies independently. When there was discordance
among the quality scores reported by the three investiga-
tors, the lowest score was adopted.
Data analyses
In combing the data, efficacy in the treatment of demen-
tia as evaluated by the SKT or ADAS-Cog in patients re-
ceiving Ginkgo biloba relative to those receiving placebo
was calculated using the SMD [15]. Data were expressed
as the SMD with 95% confidence intervals (CI). We
adopted the SMD rather than odds ratio (OR) because
the SMD represents the actual difference in the antide-
mentia effect, i.e., in the SKT or ADAS-Cog score as a
clinical outcome endpoint, thus giving a more realistic
picture of the impact of improvement as a clinically ob-
servable outcome. A negative value of the pooled SMDs
indicates greater improvement of dementia symptoms in
patients who received Ginkgo biloba therapy relative to
those who did not, whereas a positive value indicates the
opposite. The statistical significance of differences be-
tween groups was evaluated using the 95% CI. Standard
errors and CIs were converted to standard deviation for
the analyses. Apart from the SMD, side effects were ana-
lyzed in terms of ORs with 95% CIs. For the meta-
analysis, heterogeneity among studies was assessed using
Q statistics, where a P value less than 0.05 was consid-
ered significant. When no significant heterogeneity was
observed regarding the risk estimates among the studies,
the fixed-effects model was applied for further analysis
[15]. When significant heterogeneity was observed, the
random effects model was applied [15]. Calculations of
pooled SMDs with 95% CIs, as well as ORs with 95% CIs,
were performed with Review Manager 5.2 (Cochrane Col-
laboration, Oxford, UK). The heterogeneity of effect size
among studies was tested. To assess potential publication
bias, funnel plots for each outcome were also examined.
Results
Among the 298 studies retrieved from the electronic da-
tabases and those retrieved from their references by
manual search, we identified 13 clinical studies that
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study (Figure 1, Table 1) [16-28]. While no language
limitation for the systematic search was set, all relevant
articles meeting the inclusion criteria were published in
English. One group of authors divided the data from the
same study and published them in four articles, as
shown in Table 1. Finally, 9 clinical studies were used in
the meta-analysis. All used EGb761, the standard extract
of Ginkgo biloba, as the study drug, and the duration of
administration ranged from 12 to 52 weeks; in 5 studies
it was administered for 24 weeks. The daily dose ranged
from 120 to 240 mg: 120 mg in 2 studies; 160 mg in 2
studies; and 240 mg in 7 studies. Three studies included
only AD, 5 included both AD and VaD, and 1 included
dementia excluding AD and VaD. The clinical outcome
endpoint was the SKT score in 7 studies and ADAS-Cog
subscale score in 2 studies.
The quality of each article was evaluated according to
the Jadad scoring system (Table 1) [14]. All 13 clinical
studies were assessed as high quality (>3 points), and 9
were included in the present meta-analysis, excluding
the 4 reporting duplicated data.
For the SMD in the SKT, Forest plots of data from all
patients, patients in the combined AD and VaD groups,
patients in the AD-alone groups, subanalysis by dose,
and subanalysis by the duration of administration are
shown in Figures 2,3,4,5 and 6, respectively. The change in
scores for the SKT in all patients ranged from –3.3 to –0.9
in the Ginkgo biloba groups and from –1.2 to 1.3 in the
placebo groups. The SMD (95% CI) for the SKT in all pa-
tients were significantly greater for Ginkgo biloba than forExcluded 
inappropri
N=266 






13 studies included in the review
Studies identified in literature search N=298  
9 studies used in meta-analysis
Figure 1 Study selection for inclusion in the present meta-analysis.placebo groups (–0.90 [–1.46, –0.34]) (Figure 2). The
change in SKT scores in combined AD and VaD ranged
from –3.3 to –1.4 in the Ginkgo biloba and from –1.0 to
1.3 in the placebo groups. The SMD for the SKT in com-
bined AD and VaD was significantly greater for Ginkgo
biloba than for placebo groups (–1.07 [–1.66, –0.47])
(Figure 3). Changes in scores in the SKT in AD ranged
from –3.3 to –2.3 in the Ginkgo biloba groups and from –
1.0 to 1.2 in the placebo groups. The SMD in the SKT in
AD was significantly greater for Ginkgo biloba than for pla-
cebo (–1.36 [–2.27, –0.46]) (Figure 4). By dose, the change
in SKT scores at 160 mg/day dose ranged from –3.3 to –
0.7 in the Ginkgo biloba and from –1.2 to 1.0 in the placebo
groups. The SMDs in the SKT at 160 mg/day were greater
for Ginkgo biloba than for placebo (–1.06 [–3.42, 1.29]). At
240 mg/day, the SMDs in the SKT ranged from –3.2 to –
1.0 in the Ginkgo biloba and from –1.2 to 1.3 in the placebo
groups. The SMDs in the SKT at a dose of 240 mg/day
were significantly greater for Ginkgo biloba than for pla-
cebo (–0.71 [–1.28, –0.14]) (Figure 5). By treatment dur-
ation, the changes in SKT scores at 12 weeks was –2.89 in
the Ginkgo biloba and 3.8 in the placebo groups. The SMD
in the SKT at 12 weeks was greater for Ginkgo biloba than
for placebo (–1.09 [–2.10, –0.08]), and at 22–24 weeks
ranged from –3.3 to –0.85 in the Ginkgo biloba and from –
1.2 to 1.0 in the placebo groups. The SMDs in the SKT at
22–24 weeks were significantly greater for Ginkgo than for
placebo (–0.87 [–1.46, –0.34]) (Figure 6).
A Forest plot of the meta-analysis of the SMD in the
ADAS-Cog at the dose of 120 mg evaluated at 26 weeks is
shown in Figure 7. The change in scores for the ADAS-(title and abstract revealed 
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Table 1 Summary of clinical studies meeting the initial inclusion criteria for this meta-analysis





















Probable AD by NINCDS-ADRDA
Possible AD with cerebrovascular
disorder by NINCDS-AIREN
Probable VaD by NINCDS-AIREN
SKT: 9–23 (moderate dementia),
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Probable VaD by NINCDS-AIREN
SKT: 9–23 (mild–moderate dementia),




Ihl et al. [18]
Total: 404
EGb 761: 202
(AD 163, VaD 39)
Placebo: 202
















Probable AD by NINCDS-ADRDA
Possible AD with cerebrovascular
disorder by NINCDS-AIREN
Probable VaD by NINCDS-AIREN
SKT: 9–23 (mild–moderate dementia),
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Possible AD with cerebrovascular
disorder by NINCDS-AIREN
Probable VaD by NINCDS-AIREN
SKT: 9–23 (mild–moderate dementia),




Napryeyenko et al. [20]
Total: 400
EGb 761: 200
(AD 106, VaD 94;
Dropped, AD 2)
Placebo: 200
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Table 1 Summary of clinical studies meeting the initial inclusion criteria for this meta-analysis (Continued)
van Dongen et al. [23]
Total: 123
EGb 761 (240 mg): 39










AD, VaD, mixed type, memory
disorder with aging, early dementia
patients (comparatively slight
dementia, if the effect of Ginkgo
biloba is marked) by DSM-III-R,
ICD-10
SKT: 8–23, GDS <11 (except for





















Schneider et al. [25]
Total: 513
EGb 761 (240 mg): 170








240 mg: 78.1 (7.0)
120 mg: 78.6 (7.0)
Placebo: 77.5 (7.4)
Ginkgo:
240 mg: 96 (56)
120 mg: 84 (50)
Placebo: 90 (52)
AD by DSM-IV
Probable AD by NINCDS-ADRDA
MMSE: 10–24 (to prevent excess
evaluation, ≥20 not included)
Ginkgo (240 mg): 24.8 (12.7)
Ginkgo (120 mg): 24.7 (11.9)
Placebo: 25.01 (11.1)
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Uncomplicated AD or multiinfarct
dementia by DSM-III-R, ICD-10 AD




Le Bars et al. [27]
Total: 309 (AD: 236)
EGb 761: 155 (AD: 120)
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NINCDS-ADRDA: Diagnosis criteria by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) working group.
AIREN: Diagnostic criteria for vascular dementia by the Association Internationale pour la Recherche et 1’Enseignement en Neurosciences (AIREN). HAMD: Hamilton Rating Scale for Depression. MMSE: Mini-Mental State















Figure 2 Meta-analysis comparing Ginkgo biloba with placebo in the SKT in all patients.
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from 0.9 to 1.0 in the placebo groups. The SMD in the
SKT at 26 weeks and 120 mg/day were greater for Ginkgo
biloba than for placebo (–0.06 [– 0.41, 0.30]), but the dif-
ference did not reach statistical significance.
For the safety analysis, the data of side effect with an
incidence of at least more than 3% from initiation of
treatment within 2 days after completion of treatment
described in each report was extracted and analyzed. A
Forest plot of the dropout rate for any reason and suba-
nalysis by dose are shown in Figure 8. The change in the
OR (95% CI) for the dropout rate was lower for Ginkgo
biloba than for placebo (OR = 0.85 [0.68, 1.06]) but was
not statistically significant. Subanalysis showed that the
change in the OR for the dropout rate for any reason by
dose was lower for Ginkgo biloba than for placebo (OR
= 0.70 [0.49, 1.01] at 120 mg/day and OR = 0.76 [0.29,
1.98] at 160 mg/day), but the difference was not statisti-
cally significant. At the dose of 240 mg/day, Ginkgo
biloba and placebo were nearly equivalent (OR = 1.02
[0.74, 1.41]). Forest plots of the dropout rate due to side
effects and subanalysis by dose are shown in Figures 9
and 10, respectively. The change in the OR for the drop-
out rate due to side effects was significantly higher for
Ginkgo biloba than for placebo (OR = 1.83 [1.04, 3.22]).
Subanalysis of the change in the OR for the dropout rate
due to side effects and dose was also higher for the
Ginkgo biloba than for the placebo groups (OR = 1.54Figure 3 Meta-analysis comparing Ginkgo biloba with placebo in the[0.77, 3.10] at 120–160 mg/day and OR = 1.90 [0.96,
3.77] at 240 mg/day), but the difference was not statisti-
cally significant.
The number and type of severe side effects are shown
in Figure 11, and the incidence of side effects reported
in more than 3% of patients is given in Figure 12. Head-
ache, dizziness, and pulmonary infections occurred in 4
studies, and elevation of blood pressure and tinnitus in
3. Meta-analysis was performed for each of these side ef-
fects. The change in the OR for the incidence of severe
side effects was lower for the Ginkgo biloba than for the
placebo groups (OR = 0.77 [0.47, 1.26]), but the differ-
ence did not reach statistical significance. Subanalysis of
the change in the OR by daily dose showed that Ginkgo
biloba and placebo were nearly equivalent (OR = 0.95
[0.43, 2.09] at 120 mg/day). The change in the OR at the
dose of 240 mg/day was lower for Ginkgo biloba than
for placebo (OR = 0.67 [0.36, 1.27]), but not statistically
significant. By specific side effects, the change in the OR
for the incidence of headache was lower for Ginkgo
biloba than for placebo (OR = 0.75 [0.44, 1.28]), but not
significantly (Figure 12). The incidence of dizziness was
significantly lower in the Ginkgo biloba than in the pla-
cebo groups (OR = 0.50 [0.35, 0.73]) (Figure 12). The in-
cidence of infectious pulmonary disease was almost the
same in the 2 groups (OR = 1.04 [0.71, 1.54]), with no
statistically significant difference (Figure 12). Although
elevation of blood pressure occurred less frequently inSKT in combined AD and VaD.
Figure 4 Meta-analysis comparing Ginkgo biloba with placebo in the SKT in AD.
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[0.44, 1.16]), the difference was not significant (Figure 12).
However, the incidence of tinnitus was significantly lower
in the Ginkgo biloba than in the placebo groups (OR =
0.38 [0.22, 0.67]) (Figure 12).
Funnel plots for each outcome showed that there was
no publication bias that could have affected the results
of this meta-analysis.
Discussion
Many clinical studies and several meta-analyses have
shown the efficacy of Ginkgo biloba for the treatment of
neuropsychiatric disorders, but almost all previous
meta-analyses evaluated multiple measures of cognitive
outcome by extracting the ADAS-Cog, SKT, etc. results
as a marker of efficacy and did not evaluate the detailed
safety outcomes. Therefore, a final conclusion has not
been reached on its benefits as a medicine based on the
balance between efficacy and safety. For the safe use of
Ginkgo biloba extract products from the viewpoint of
both patients and healthcare professionals, it is import-
ant to know the risk-and-benefit balance and the mostFigure 5 Meta-analysis comparing Ginkgo biloba with placebo in theeffective method of administration in patients with de-
mentia. By evaluating both the efficacy by a single meas-
ure of cognitive outcome and safety by detailed safety
outcomes of Ginkgo biloba, this meta-analysis yielded
results similar to previous ones and suggested that
Ginkgo biloba has therapeutic potential for the treat-
ment of dementia.
Thirteen clinical studies retrieved from the literature
satisfied the predetermined inclusion criteria, and 9 were
used in the present meta-analysis, excluding 4 reports
based on the same data. Previous meta-analyses included
6–9 clinical studies of dementia. Disease classification in
our meta-analysis included 3 reports on AD alone, 5 on
combined AD and VaD, and 1 report on other dementia.
The meta-analysis results for the SMD in the SKT be-
tween Ginkgo biloba and placebo in all patients, the AD
and VaD combined group, and AD-alone group showed a
statistically significant difference favoring Ginkgo biloba
over placebo. Because a higher SKT score indicates a more
severe level of dementia [29], these results suggest that
Ginkgo biloba can improve the symptoms of AD and/or
VaD. They were generally consistent with the results ofSKT at doses of 160 and 240 mg.
Figure 6 Meta-analysis comparing Ginkgo biloba with placebo in the SKT at 12 weeks and 22–24 weeks of administration.
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was –1.30 (95% CI: –3.10, 0.50] [11].
When conducting subgroup analysis by dose, the SMD
(95% CI) in the SKT at 160 mg and 240 mg were –1.06
(–3.42, 1.29) and –0.71 (–1.28, –0.14), respectively, with
a statistically significant difference only between the latter
and placebo. Jiang et al. [10] reported a similar result when
comparing changes in cognitive scores in patients who
received Ginkgo biloba >200 mg/day and <200 mg/day.
The effects of Ginkgo biloba on the central nervous sys-
tem as measured in the brain wave test suggested dose
responsiveness [30], and the present results may par-
tially support that although we found no clear dose-
response difference between the doses of 160 mg and
240 mg daily.
There was no statistically significant difference in the
ADAS-Cog results (–0.06 [–0.41, 0.30]) in our meta-
analysis, although a tendency toward improvement was
noted in the Ginkgo biloba group. Two studies included
in this meta-analysis had similar patient numbers but
conflicting ADAS-Cog results. A possible reason for this
may have been differing diagnostic criteria and the dosage
used. The dose in both of those studies was 120 mg daily,
while our SKT results indicated the efficacy of GinkgoFigure 7 Meta-analysis comparing Ginkgo biloba with placebo in thebiloba 240 mg daily. It appears likely that a full response
was not achieved with a daily dose of 120 mg.
The dropout rate for any reason in all combined stud-
ies had an OR of 0.85 (95% CI: 0.67, 1.08) and the drop-
out rate at doses of 120 mg/day, 160 mg/day, and 240
mg/day, which showed efficacy in the SKT results, were
0.70 (0.49, 1.01), 0.76 (0.29, 1.98), and 1.02 (0.74, 1.41), re-
spectively. None of the studies at doses of 120 mg/day,
160 mg/day, and 240 mg/day in this meta-analysis showed
a statistically significant difference in dropout rates for any
reason compared with placebo. The OR of the dropout
rate due to side effects in all combined studies was 1.83
(1.04, 3.22) and there was a statistically significant differ-
ence between Ginkgo biloba and placebo. Although there
was no significant difference between Ginkgo biloba and
placebo in subanalysis of the doses of 120–160 mg/day
and 240 mg/day, these data showed that the incidence of
side effects in Ginkgo biloba groups tended to be higher
than that in placebo groups. A tendency for a dose-
response relationship in the dropout rate due to side ef-
fects was also suggested.
There was no significant difference between the Ginkgo
biloba and placebo groups in the occurrence of severe side
effects, in the incidence of side effects reported in 3 orADAS-Cog at 26 weeks at a dose of 120 mg.
Figure 8 Meta-analysis comparing Ginkgo biloba with placebo by dropout rate for any reason at doses of 120, 160, and 240 mg.
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tients from the beginning of treatment until 2 days after the
end of the studies analyzed. In the meta-analysis for each
side effect including headache, pulmonary infection, and
elevation of blood pressure, no significant differences were
found between Ginkgo biloba and placebo. On the other
hand, the cumulative OR (95% CI) for dizziness and tin-
nitus was 0.50 (0.35, 0.73) and 0.38 (0.22, 0.67), respectively,
indicating a significantly lower incidence in the GinkgoFigure 9 Meta-analysis comparing Ginkgo biloba with placebo by drobiloba compared with the placebo groups. Commission E
of Germany also found that the treatment of dementia
with Ginkgo biloba was not associated with the occur-
rence of dizziness and tinnitus. This study confirmed the
preventive effect of Ginkgo biloba against dizziness and
tinnitus. It is also known that many elderly people experi-
ence dizziness and tinnitus, and thus Ginkgo biloba prepa-
rations would be advantageous in preventing these side
effects in those with dementia.pout rate due to side effects.
Figure 10 Meta-analysis comparing Ginkgo biloba with placebo by dropout rate due to side effects at doses of 120–160 and 240 mg.
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Similar to the evaluation of other antidementia agents
using the SMD at baseline and SKD and ADAS-Cog
scores after treatment as clinical outcomes, it should be
noted that the extent of treatment effect differs depending
on baseline values. Although there was little difference in
the baseline values in the studies included this meta-
analysis, the study protocols, severity of disease, areasFigure 11 Meta-analysis comparing Ginkgo biloba with placebo in thwhere the studies were performed, etc. differed. Therefore,
we used the random-effect model in meta-analysis after
determining the heterogeneity of the studies.
In summary, Ginkgo biloba appears more effective
than placebo in the treatment of dementia at doses of
more than 240 mg daily administered for 22 weeks when
using the SKT as a cognitive outcome measure, and
safety did not differ markedly between them.e occurrence of severe side effects.
a Headache 
b Dizziness 
c Pulmonary infectious disease 
d Elevation of blood pressure 
e Tinnitus 
Figure 12 Meta-analysis comparing Ginkgo biloba with placebo in the occurrence of specific side effects. a: Headache; b: Dizziness;
c: Pulmonary infectious disease; d: Elevation of blood pressure; e: Tinnitus.
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Taking a 240-mg daily dose of Ginkgo biloba extract is
effective in the treatment of dementia. Ginkgo biloba ex-
tract is therefore useful in improving the symptoms of
dementia, as found in previous reports of meta-analyses.
The evidence for efficacy and safety found in the present
meta-analysis of the effects of Ginkgo biloba extract
contributes to knowledge of the treatment of dementia.
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